



**MARICO LIMITED**

**PART I**

**STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2013.**

Particulars	Quarter ended			Year ended	
	March 31, 2013 (Unaudited) (Note 17)	December 31, 2012 (Unaudited)	March 31, 2012 (Unaudited) (Note 17)	March 31, 2013 (Audited)	March 31, 2012 (Audited)
<b>1 Income from operations (Note 5)</b>					
a. Net Sales / Income from Operations (Net of excise duty)	99,725.57	1,16,399.13	90,936.94	4,58,434.93	3,96,819.71
b. Other operating income	133.59	380.33	379.00	1,184.02	1,146.91
<b>Total income from operations (net)</b>	<b>99,859.16</b>	<b>1,16,779.46</b>	<b>91,315.94</b>	<b>4,59,618.95</b>	<b>3,97,966.62</b>
<b>2. Expenses</b>					
a. Cost of materials consumed	53,123.17	53,546.95	52,688.38	2,22,079.47	2,16,488.49
b. Purchases of stock-in-trade	1,678.93	1,954.41	433.89	11,659.62	1,744.35
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade (Increase) / decrease	(10,704.32)	314.96	(9,484.99)	(12,746.05)	(5,078.08)
d. Employee benefits expenses	9,867.65	9,039.62	8,361.87	38,055.29	30,728.85
e. Depreciation and amortization expense (Note 11(a))	2,533.12	1,950.34	1,906.06	8,662.36	7,252.28
f. Advertisement & Sales Promotion	12,567.85	15,781.77	11,307.11	59,793.78	42,581.89
g. Other expenses	21,297.43	19,620.93	16,752.29	78,197.16	63,062.00
<b>Total Expenses</b>	<b>90,363.83</b>	<b>1,02,208.98</b>	<b>81,964.61</b>	<b>4,05,701.63</b>	<b>3,56,779.78</b>
<b>3 Profit from operations before other income, finance costs and Exceptional Items (1-2)</b>	<b>9,495.33</b>	<b>14,570.48</b>	<b>9,351.33</b>	<b>53,917.32</b>	<b>41,186.84</b>
<b>4 Other Income</b>	<b>1,016.77</b>	<b>891.83</b>	<b>790.59</b>	<b>3,752.84</b>	<b>3,257.38</b>
<b>5 Profit from ordinary activities before finance costs and Exceptional Items (3+4)</b>	<b>10,512.10</b>	<b>15,462.31</b>	<b>10,141.92</b>	<b>57,670.16</b>	<b>44,444.22</b>
<b>6 Finance costs</b>	<b>1,126.46</b>	<b>1,402.67</b>	<b>1,130.59</b>	<b>5,802.63</b>	<b>4,238.23</b>
<b>7 Profit from ordinary activities after finance costs but before Exceptional Items (5-6)</b>	<b>9,385.64</b>	<b>14,059.64</b>	<b>9,011.33</b>	<b>51,867.53</b>	<b>40,205.99</b>
<b>8 Exceptional items (Note 11)</b>	<b>3,320.60</b>	<b>-</b>	<b>(175.28)</b>	<b>3,320.60</b>	<b>(175.28)</b>
<b>9 Profit from ordinary activities before Tax (7+8) (Note 5)</b>	<b>12,706.24</b>	<b>14,059.64</b>	<b>8,836.05</b>	<b>55,188.13</b>	<b>40,030.71</b>
<b>10 Tax expense (net of MAT credit entitlement) (Note 10)</b>	<b>4,057.25</b>	<b>3,603.84</b>	<b>1,887.63</b>	<b>14,619.03</b>	<b>7,824.42</b>
<b>11 Net Profit from ordinary activities after Tax (9-10) (Note 5)</b>	<b>8,648.99</b>	<b>10,455.80</b>	<b>6,948.42</b>	<b>40,569.10</b>	<b>32,206.29</b>
<b>12 Extraordinary item (net of tax)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>13 Net Profit for the period / year (11-12)</b>	<b>8,648.99</b>	<b>10,455.80</b>	<b>6,948.42</b>	<b>40,569.10</b>	<b>32,206.29</b>
<b>14 Share of profit / (loss) of associates</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>15 Minority Interest</b>	<b>262.69</b>	<b>226.50</b>	<b>(21.29)</b>	<b>982.63</b>	<b>495.17</b>
<b>16 Net Profit after taxes, minority interest and share of profit / (loss) of associates (13±14-15)</b>	<b>8,386.30</b>	<b>10,229.30</b>	<b>6,969.71</b>	<b>39,586.47</b>	<b>31,711.12</b>
<b>17 Paid-up Equity Share Capital (Note 7)</b> (Face Value Re. 1 per share)	<b>6,447.72</b>	<b>6,447.08</b>	<b>6,149.34</b>	<b>6,447.72</b>	<b>6,149.34</b>
<b>18 Reserves excluding Revaluation Reserves (as per Balance Sheet)</b>				<b>1,91,704.32</b>	<b>1,08,151.95</b>
<b>19 Earnings Per Share (EPS)</b>					
i EPS before Extraordinary items for the period / year					
(a) Basic	1.30	1.59	1.13	6.18	5.16
(b) Diluted	1.30	1.59	1.13	6.17	5.15
ii EPS after Extraordinary items for the period / year					
(a) Basic	1.30	1.59	1.13	6.18	5.16
(b) Diluted	1.30	1.59	1.13	6.17	5.15



## PART II

## SELECT INFORMATION FOR THE QUARTER AND YEAR ENDED MARCH 31, 2013.

Particulars	Quarter ended			Year ended	
	March 31, 2013 (Unaudited)	December 31, 2012 (Unaudited)	March 31, 2012 (Unaudited)	March 31, 2013 (Audited)	March 31, 2012 (Audited)
<b>A PARTICULARS OF SHAREHOLDING</b>					
<b>1 Public shareholding</b>					
- Number of shares	25,96,53,279	25,95,89,079	22,91,95,867	25,96,53,279	22,91,95,867
- Percentage of shareholding	40.27	40.26	37.27	40.27	37.27
<b>2 Promoters &amp; Promoter Group Shareholding</b>					
<b>(a) Pledged / Encumbered</b>					
- Number of Shares	-	-	-	-	-
- Percentage of Shares (as a % of total shareholding of promoters and promoter group)	-	-	-	-	-
- Percentage of Shares (as a % of total share capital of the company)	-	-	-	-	-
<b>(b) Non-encumbered</b>					
- Number of Shares	38,51,18,520	38,51,18,520	38,57,38,520	38,51,18,520	38,57,38,520
- Percentage of Shares (as a % of total shareholding of promoters and promoter group)	100.00	100.00	100.00	100.00	100.00
- Percentage of Shares (as a % of total share capital of the company)	59.73	59.74	62.73	59.73	62.73

PARTICULARS	Quarter Ended March 31, 2013
<b>B INVESTOR COMPLAINTS</b>	
Pending at the beginning of the quarter	NIL
Received during the quarter	10
Disposed of during the quarter	10
Remaining unresolved at the end of the quarter	NIL





**MARICO LIMITED**

(Rs. in Lacs)

**STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2013.**

Particulars	Quarter ended			Year ended	
	March 31, 2013 (Unaudited) (Note 17)	December 31, 2012 (Unaudited)	March 31, 2012 (Unaudited) (Note 17)	March 31, 2013 (Audited)	March 31, 2012 (Audited)
<b>1. Segment Revenue (Note 4)</b>					
(a) Consumer Products					
i. Domestic	69,746.66	82,824.97	62,049.32	3,25,258.03	2,76,594.05
ii. International	21,579.55	26,102.92	21,821.38	1,00,759.96	93,545.54
	91,326.21	1,08,927.89	83,870.70	+26,017.99	3,70,139.59
(b) Skin Care	8,532.95	7,851.57	7,445.24	33,600.96	27,827.03
<b>Sub - total</b>	<b>99,859.16</b>	<b>1,16,779.46</b>	<b>91,315.94</b>	<b>4,59,618.95</b>	<b>3,97,966.62</b>
Less: Inter Segment revenue	-	-	-	-	-
<b>Net Sales / Income from Operations</b>	<b>99,859.16</b>	<b>1,16,779.46</b>	<b>91,315.94</b>	<b>4,59,618.95</b>	<b>3,97,966.62</b>
<b>2. Segment Result (Note 4)</b>					
<b>(Profit before Interest and Tax and exceptional items)</b>					
(a) Consumer Products					
i. Domestic	12,646.17	14,487.35	10,858.74	58,123.37	44,428.04
ii. International	336.94	2,288.71	1,311.84	6,641.37	7,993.44
	12,983.12	16,776.06	12,170.58	64,764.74	52,421.48
(b) Skin Care	(160.52)	393.12	(380.42)	75.54	(2,907.32)
<b>Sub - total</b>	<b>12,822.60</b>	<b>17,169.18</b>	<b>11,790.16</b>	<b>64,840.28</b>	<b>49,514.16</b>
Less: Interest (net)	451.94	836.71	722.15	3,511.20	2,482.80
Add: Un-allocable income	94.83	57.72	420.70	845.52	1,215.15
Less: Un-allocable expense	(3,079.85)	(2,330.55)	(2,477.38)	(10,307.07)	(8,040.52)
<b>Total Profit before Tax and Exceptional Items</b>	<b>9,385.64</b>	<b>14,059.64</b>	<b>9,011.33</b>	<b>51,867.53</b>	<b>40,205.99</b>
<b>3. Capital Employed (Segment Assets - Segment Liabilities) (Note 4)</b>					
(a) Consumer Products					
i. Domestic	1,53,088.84	1,34,579.37	60,867.92	1,53,088.84	60,867.92
ii. International	48,526.48	52,144.31	59,496.89	48,526.48	59,496.89
	2,01,615.32	1,86,723.68	1,20,364.81	2,01,615.32	1,20,364.81
(b) Skin Care	14,155.14	18,952.95	19,238.54	14,155.14	19,238.54
Add: Unallocated Capital Employed	(17,618.42)	(15,514.65)	(25,302.06)	(17,618.42)	(25,302.06)
	<b>1,98,152.04</b>	<b>1,90,161.98</b>	<b>1,14,301.29</b>	<b>1,98,152.04</b>	<b>1,14,301.29</b>



Particulars		As at	
		March 31, 2013	March 31, 2012
		Audited	Audited
<b>A</b>	<b><u>EQUITY AND LIABILITIES</u></b>		
<b>1</b>	<b>Shareholder's funds</b>		
	(a) Share capital (Note 7 and 14)	6,447.72	6,149.34
	(b) Reserves and surplus (Notes 7, 12 and 14)	191,704.32	108,151.95
	<b>Sub - total Shareholder's Fund</b>	<b>198,152.04</b>	<b>114,301.29</b>
<b>2</b>	<b>Minority interest</b>	3,513.68	2,489.66
<b>3</b>	<b>Non- current liabilities</b>		
	(a) Long-term borrowings (Note 15)	43,262.71	39,066.92
	(b) Deferred Tax liabilities (Net)	578.70	-
	(c) Other Long-term liabilities	98.10	62.70
	(d) Long-term provisions	1,047.89	4,193.96
	<b>Sub - total Non-current Liabilities</b>	<b>44,987.40</b>	<b>43,323.58</b>
<b>4</b>	<b>Current Liabilities</b>		
	(a) Short-term borrowings	35,806.71	37,158.78
	(b) Trade payables	47,846.52	35,836.70
	(c) Other current liabilities	29,326.20	20,818.63
	(d) Short-term provisions	11,089.09	7,772.92
	<b>Sub - total Current Liabilities</b>	<b>124,068.52</b>	<b>101,587.03</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>370,721.64</b>	<b>261,701.56</b>
<b>B</b>	<b><u>ASSETS</u></b>		
<b>1</b>	<b>Non-current assets</b>		
	(a) Fixed assets (Notes 6, 9 and 11)	142,243.95	50,185.43
	(b) Goodwill on consolidation	39,551.28	39,548.58
	(c) Non-current investments	3,802.72	2,938.40
	(d) Deferred tax assets (net)	-	2,234.34
	(e) Long-term loans and advances	11,939.23	12,439.80
	(f) Other non-current assets	14,261.39	12,340.21
	<b>Sub - total Non-current Assets</b>	<b>211,798.57</b>	<b>119,686.76</b>
<b>2</b>	<b>Current assets</b>		
	(a) Current investments	11,361.48	26,625.60
	(b) Inventories	86,269.16	72,021.00
	(c) Trade receivables	19,655.28	20,828.37
	(d) Cash and cash equivalents	26,673.48	13,209.20
	(e) Short-term loans and advances	13,607.51	7,510.38
	(f) Other current assets	1,356.16	1,820.25
	<b>Sub - total Current Assets</b>	<b>158,923.07</b>	<b>142,014.80</b>
	<b>TOTAL - ASSETS</b>	<b>370,721.64</b>	<b>261,701.56</b>



Notes to Consolidated financial results:

1. The information presented for the year ended March 31, 2013 is extracted from the audited financial statements for the year ended March 31, 2013. The said financial statements and results for the year ended March 31, 2013 were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on April 30, 2013.
2. The Company has opted to publish unaudited quarterly and audited consolidated financial results for the year ended March 31, 2013 pursuant to option made available as per clause 41 of the Listing Agreement. The audited Standalone financial results for the year ended March 31, 2013 are available on the Company's website - <http://www.marico.com> and on the websites of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)).
3. The Consolidated financial results for the quarter and year ended March 31, 2013 comprise results of Marico Limited and its subsidiaries and step down subsidiaries in India, Bangladesh, UAE, Egypt, South Africa, Malaysia, Singapore and Vietnam. All the aforesaid entities are collectively called 'Marico'.
4. The primary reporting of consolidated financial results of Marico is based on two business segments namely "Consumer Products" and "Skin Care". The Company has bifurcated the financial results of its Consumer Product business segment into India Business and International Business, by way of providing supplementary information.

During the current year, the Company has categorised certain corporate/ common expenses and assets/ liabilities as un-allocable having regard to the nature of such items, which hitherto were allocated to consumer product business segment. Consequently previous period/ year figures have been reclassified to conform to the current period figures.

5. On January 7, 2013, the Board of Directors' of Marico Limited approved a Scheme of Arrangement for demerger of the business undertaking of Kaya ("Kaya Business") with effect from appointed date, April 1, 2013 ('the Scheme') subject to all regulatory and statutory approvals. The Scheme envisages the de-merger of Kaya Business into a new company, "Marico Kaya Enterprises Limited ('MaKE')", which was incorporated on January 19, 2013 for the purpose. As a consideration, the shareholders of Marico Limited as on the record date shall be issued 1 share of MaKE with a face value of Rs. 10 each for every 50 shares of Marico with a face value of Re. 1 each. Consequently, the shareholding structure of MaKE will mirror the shareholding structure of Marico Limited.

Kaya business relate to the skin care segment and comprise the results of Kaya Limited, Kaya Middle East FZE, Derma-Rx International Aesthetics Pte. Ltd, The Drx Clinic Pte.Ltd, The DRx Medispa Pte. Ltd, DRx Investments Pte. Ltd. And Drx Aesthetics sdn. Bhd.

Given below are the results of the Kaya Business included in the Consolidated Financial Results for each of the periods represented:




(Rs. in Lacs)

Particulars	Quarter ended			Year ended	
	March 31, 2013	December 31, 2012	March 31, 2012	March 31, 2013	March 31, 2012
Net Sales / Income from Operations	8,532.95	7,851.57	7,445.24	33,600.96	27,827.02
Profit from ordinary activities before tax	(2,650.18)	33.66	(856.47)	(3,311.77)	(3,994.83)
Profit from ordinary activities after tax	(2,682.67)	(60.76)	(871.03)	(3,704.14)	(4,377.88)

The carrying value of assets and liabilities relating to Kaya business as at March 31, 2013 is Rs. 35,503.19 lacs and Rs. 23,706.94 lacs, respectively.

6. The Company, on May 29, 2012, concluded the effective acquisition of the personal care business of Paras Pharmaceuticals Limited ("PPL") for a consideration of Rs. 74,560 lacs. The acquisition was effected through Marico Consumer Care Limited ("MCCL"), a wholly owned subsidiary of the Company. MCCL was incorporated on April 20, 2012 and acquired 100 % equity stake in Halite Personal Care India Private Limited ("Halite") from Halite's erstwhile owners. The personal care business had been demerged from PPL into Halite effective March 1, 2012 under a Scheme of Amalgamation and Arrangement approved by the High Court of Punjab and Haryana.
7. The shareholders of the Company, at their meeting held on May 2, 2012, approved issue of equity shares on preferential allotment basis aggregating Rs. 50,000 lacs at a price of Rs. 170 per equity share to two overseas investors for funding a part of the Halite acquisition. Subsequently, the Company allotted 29,411,764 equity shares of face value Re. 1 each at a share premium of Rs. 169 each to these investors on May 16, 2012. This resulted in increase of equity share capital by Rs. 294.12 lacs and securities premium reserve by Rs. 49,705.88 lacs. The proceeds of the issue together with internal accruals were infused by Marico as equity investment in MCCL. MCCL utilized the equity proceeds for acquiring 100% equity stake in Halite on May 29, 2012.
8. The shareholders of Halite vide a special resolution at their extra ordinary general meeting held on January 18, 2013, resolved that the company be voluntarily liquidated. The shareholders also appointed a liquidator. In view of the liquidation, the liquidator, on March 25, 2013, distributed the assets of Halite (viz. intellectual property rights, cash at bank and tangible fixed assets) to MCCL, being the sole shareholder of Halite. MCCL has taken over assets of Halite at fair values, determined by an independent valuer, as applicable. On distribution, MCCL received assets in excess of its Equity investment in Halite, resulting in profit of Rs. 591.33 lacs, which is shown as an exceptional item. (Refer Note 11)
9. During the quarter ended June 30, 2012, the Company acquired commercial premises for a new office building for a consideration of Rs. 12,083.12 lacs.



10. Tax expenses for the year ended March 31, 2012 are net of write back of excess provision of Rs. 556.29 Lacs relating to the previous year.
11. "Exceptional Items" for the quarter and year ended March 31, 2013 and March 31, 2012 comprised the following.

Rs. Lacs

	Quarter and year ended	
	March 31, 2013	March 31, 2012
Surplus on change in method of depreciation (Refer note (a) below)	3,745.05	Nil
Impairment loss relating to Kaya Skin Clinics in India / Middle East (Refer note (b) below)	(1,745.97)	(175.28)
Incremental provision towards contingent consideration relating to DRx entity- Singapore	(175.06)	Nil
Profit on distribution of assets by Halite to MCCL on voluntary liquidation (Refer note 8)	591.33	Nil
Reversal of impairment loss on "Fiancee" trademark (Refer note (c) below)	905.25	Nil
<b>Total</b>	<b>3,320.60</b>	<b>(175.28)</b>

(a) Effective January 1, 2013, the Company has retrospectively changed its method of providing depreciation on Factory Building and Plant & Machinery from the 'Written Down Value Method' to 'Straight Line Method' at the rates prescribed in Schedule XIV to the Companies Act, 1956. This change results in a more appropriate presentation and will give a systematic basis of depreciation charge, representative of the time pattern in which the economic benefits flow to the Company. Accordingly, the Company has recognised the surplus of Rs. 3,745.05 lacs arising from this retrospective change.

Had the previous method of depreciation been followed, depreciation charge for the quarter and year ended March 31, 2013 would have been higher by Rs. 296.48 lacs and the profit before tax for the current quarter and year ended March 31, 2013 would have been lower by of an equivalent amount.

(b) The management has, as in the previous year, carried out impairment assessment in respect of Skin business at the clinic level, which the management considers as the relevant cash generating unit. This resulted in an impairment provision of Rs. 1,745.97 lacs (Rs. 175.28 lacs) which is included in "Exceptional Items" in the Statement of Profit and Loss.

(c) During the year ended March 31, 2011, the Company had recognised an impairment loss of Rs. 1,388.05 lacs towards brand "Fiancee". During the current quarter, the Company has reassessed the value in use and accordingly reversed an impairment loss of Rs. 905.25 lacs.



12. Pursuant to the Announcement of the Institute of Chartered Accountants of India's ("ICAI") "Accounting for Derivatives" on encouraging the early adoption of Accounting Standard 30 ("AS 30"), "Financial Instruments: Recognition and Measurement", the Company had, commencing from the year ended March 31, 2009, decided on early adoption of AS 30 to the extent it does not conflict with existing mandatory accounting standards and other authoritative pronouncements, Company Law and other regulatory requirements. Accordingly, the net unrealised gain/ (loss) of Rs.(5,249.45) lacs as at March 31, 2013, Rs. (5,830.37) lacs as at December 31, 2012 [Rs. (3,392.52) lacs as at March 31, 2012 and Rs. (4,949.97) lacs as at December 31, 2011] in respect of outstanding derivative instruments and foreign currency loans at the respective period end which qualify for hedge accounting, stands in the 'Hedge Reserve', which would be recognised in the Statement of Profit and Loss on occurrence of the underlying transactions or forecast revenue.

13. Following are the particulars of the Company (on a standalone basis) :

(Rs. In Lacs)

Particulars	Quarter ended			Year ended	
	March 31, 2013	December 31, 2012	March 31, 2012	March 31, 2013	March 31, 2012
Net Sales / Income from Operations	73,133.08	86,791.19	67,582.61	339,882.53	295,821.05
Profit before tax	14,471.19	13,688.96	10,784.90	54,198.05	39,927.39
Profit after tax	11,060.51	11,016.81	8,770.84	42,908.58	33,658.43

14. Stock Options were granted up to March 31, 2013 to certain eligible employees of the Company pursuant to the "Marico Employees' Stock Options Scheme 2007" ("the Scheme"). In all, 11,376,300 options were granted up to March 31, 2013 of which 4,663,600 options have been forfeited and 6,360,035 options have been exercised. During the quarter and the year ended March 31, 2013, pursuant to the exercise of the stock options, the Company has allotted 64,200 and 425,648 equity shares of Re. 1 each, respectively, to employees resulting in increase in paid-up share capital by Rs. 4.26 lacs and securities premium reserve by Rs. 241.99 lacs. 352,665 options were outstanding as at March 31, 2013.
15. During the quarter ended March 31, 2013 the Company allotted 1,000, Unsecured, Zero Coupon Redeemable Non- convertible debentures of Rs. 1,000,000 each, aggregating Rs. 10,000 lacs which are listed on National Stock Exchange of India Limited.
16. At its meeting held on April 30, 2013 the Board of Directors of Marico Limited declared a 2nd interim dividend of 50% (Re. 0.50 per share of Re. 1 each) on paid-up equity capital of Rs. 6,447 Lacs. The dividend shall be paid to those shareholders whose names appear in the Register of Members as on May 6, 2013.
17. The figures for the quarter ended March 31, 2013 and March 31, 2012 are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the third quarter of relevant financial year.





18. Previous periods / year figures have been regrouped / reclassified to make them comparable with those of current period / year.
19. These Financial Results and other related useful information are available on Marico's website - <http://www.marico.com>.

Place: Mumbai

Date: April 30, 2013

  
Harsh C. Mariwala



Chairman & Managing Director

Marico (BSE: 531642, NSE: "MARICO") is one of India's leading Consumer Products & Services Group, in the global beauty and wellness space. During 2012-13, Marico recorded a turnover of Rs. 46 billion (USD 836 Million) through its products and services sold in India and about 25 other countries in Asia and Africa.

Marico touches the lives of 1 out of every 3 Indians, through its portfolio of brands such as Parachute, Parachute Advansed, Saffola, Hair & Care, Nihar, Livon, Setwet, Zatak, Mediker, Revive and Manjal. The international consumer products portfolio contributes to about 242% of the Group's revenue, with brands like Parachute, HairCode, Fiancée, Caivil, Hercules, Black Chic, Code 10, Ingwe, X-Men, L'Ovite and Thuan Phat.

Marico's focus on sustainable profitable growth is manifest through its consistent financial performance, a CAGR of 19% in Turnover and Profits over the past 5 years.

"As part of Marico's Green Initiative your Company wants to make its contribution to save the environment by sending its shareholders the Annual Report and other communication using the electronic medium. Therefore, we request you to update your email addresses with your respective Depository Participant (DP) where you hold your DEMAT accounts. Alternatively, you can mail us at [investor@maricoindia.net](mailto:investor@maricoindia.net) with your email address, Name, DP ID and Client ID. We thank you for supporting this Green Initiative."

Registered Office: "Rang Sharda", Krishnachandra Marg, Bandra Reclamation, Bandra (West), Mumbai - 400050, India.

Email: [investor@maricoindia.net](mailto:investor@maricoindia.net)

Websites: [www.marico.com](http://www.marico.com), [www.maricoinnovationfoundation.org](http://www.maricoinnovationfoundation.org), [www.parachuteadvansed.com](http://www.parachuteadvansed.com), [www.saffolalife.com](http://www.saffolalife.com) and [www.kayaclinic.com](http://www.kayaclinic.com)